SSY Group Ltd banner
S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 2.35 HKD -1.26%
Market Cap: HK$6.8B

SSY Group Ltd
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

SSY Group Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Other Long-Term Assets
HK$63m
CAGR 3-Years
-19%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
Other Long-Term Assets
$93k
CAGR 3-Years
-5%
CAGR 5-Years
36%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Other Long-Term Assets
HK$1.1B
CAGR 3-Years
1%
CAGR 5-Years
28%
CAGR 10-Years
13%
Sino Biopharmaceutical Ltd
HKEX:1177
Other Long-Term Assets
¥562.4m
CAGR 3-Years
-18%
CAGR 5-Years
-32%
CAGR 10-Years
0%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Other Long-Term Assets
HK$7.2B
CAGR 3-Years
10%
CAGR 5-Years
17%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Other Long-Term Assets
$32.7m
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
17%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
6.8B HKD
Industry
Pharmaceuticals

SSY Group Ltd. stands out as a significant player in the Chinese pharmaceutical industry, seamlessly interweaving its intricate supply chain operations with its robust manufacturing capabilities. Founded in 1994, the company has its roots in the scenic Hebei Province and has evolved into a powerful force in the realm of injectable pharmaceuticals and oral solutions. The organization primarily operates through its core segment—manufacturing and distributing intravenous infusion solutions. By leveraging cutting-edge technology and adhering to stringent quality standards, SSY Group has managed to capture a sizable share of the domestic market, ensuring a steady stream of revenue. The firm's prowess isn't limited to its pharmaceutical expertise. SSY Group's growth strategy involves a careful blend of organic expansion and strategic acquisitions, which enables it to broaden its product categories and penetrate new regional markets. By offering a wide variety of products ranging from antibiotics to anti-infection drugs, the company adeptly meets diverse healthcare needs while simultaneously driving profitability. Additionally, SSY Group bolsters its financial performance through its involvement in both research and development. By dedicating resources toward innovation, it aspires to maintain its competitive edge, producing high-value products that facilitate sustainable long-term growth. Thus, SSY Group's tightly-knit approach to blending manufacturing excellence with strategic growth initiatives paints a picture of a company adeptly navigating the challenges and opportunities of the healthcare sector.

Intrinsic Value
3.49 HKD
Undervaluation 33%
Intrinsic Value
Price HK$2.35
S

See Also

What is SSY Group Ltd's Other Long-Term Assets?
Other Long-Term Assets
63m HKD

Based on the financial report for Dec 31, 2025, SSY Group Ltd's Other Long-Term Assets amounts to 63m HKD.

What is SSY Group Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
-14%

Over the last year, the Other Long-Term Assets growth was -53%. The average annual Other Long-Term Assets growth rates for SSY Group Ltd have been -19% over the past three years , -15% over the past five years , and -14% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett